Interstitial cystitis (IC), a chronic inflammatory condition of the urinary bladder characterized by pain and difficulties with urination, has limited treatment options. Beta-caryophyllene (BCP) is a sesquiterpene with anti-inflammatory and analgesic properties, but has poor water solubility and limited intestinal absorption which may limit oral bioavailability. Indena Phytosome® is a proprietary food-grade lecithin-based delivery system that optimizes the bioavailability and pharmacokinetic profile of natural phytochemicals like BCP by producing a stable solid dispersion suitable for oral delivery.
Objective
To examine the therapeutic potential of an oral BCP Indena Phytosome® formulation (BCP Indena Phytosome®) for the treatment of IC.
Methods
Female BALB/c mice were pre-treated with BCP Indena Phytosome® or empty Indena Phytosome® vehicle, then IC was induced using lipopolysaccharide. 24 h later, inflammation was evaluated using intravital microscopy and histology. Pain was evaluated using behavior scoring and von Frey asethesiometry.
Results
Pre-treatment with BCP Indena Phytosome® reduced leukocyte adhesion, histology scores, and behavior scores in IC mice, indicating a reduction in inflammation and pain. Lipopolysaccharide administration did not alter leukocyte rolling, capillary perfusion, or von Frey scores.
Conclusions
Oral BCP Indena Phytosome® effectively reduces pain and inflammation in experimental IC by decreasing leukocyte adhesion and extravasation in the bladder.
HannoP. International consultation on IC – Rome, September 2004 / forging an international consensus: progress in painful bladder syndrome / interstitial cystitis. Int Urogynecol J2005; 16: S2–S5.
2.
GrundyLCaldwellABrierleySM. Mechanisms underlying overactive bladder and interstitial cystitis/painful bladder syndrome. Front Neurosci2018; 12. doi:10.3389/fnins.2018.00931
LavelleJPMeyersSARuizWG, et al.Urothelial pathophysiological changes in feline interstitial cystitis: a human model. Am J Physiol Renal Physiol2000; 278: F540–F553.
5.
MaedaDAkiyamaYMorikawaT, et al.Hunner-Type (classic) interstitial cystitis: a distinct inflammatory disorder characterized by pancystitis, with frequent expansion of clonal B-cells and epithelial denudation. PLoS One2015; 10: e0143316.
6.
GroverSSrivastavaALeeR, et al.Role of inflammation in bladder function and interstitial cystitis. Ther Adv Urol2011; 3: 19–33.
7.
TheoharidesTCKempurajDSantGR. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology2001; 57: 47–55.
8.
AbernethyMGRosenfeldAWhiteJR, et al.Urinary microbiome and cytokine levels in women with interstitial cystitis. Obstet Gynecol2017; 129: 500–506.
9.
LotzMVilligerPHugliT, et al.Interleukin-6 and interstitial cystitis. J Urol1994; 152: 869–873.
10.
KimAHanJYRyuCM, et al.Histopathological characteristics of interstitial cystitis/bladder pain syndrome without hunner lesion. Histopathology2017; 71: 415–424.
11.
SuskindAMBerrySHSuttorpMJ, et al.Health-related quality of life in patients with interstitial cystitis/ bladder pain syndrome and frequently associated comorbidities. Qual Life Res2013; 22: 1537–1541.
12.
BerrySHHayesRDSuttorpM, et al.Health-Related quality of life impact of interstitial cystitis/painful bladder syndrome and other symptomatic pelvic disorders. J Urol2009; 181: 90–91.
13.
HannoPMEricksonDMoldwinR, et al.Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol2015; 193: 1545–1553.
14.
ClemensJQLinkCLEggersPW, et al.Prevalence of painful bladder symptoms and effect on quality of life in black, hispanic and white men and women. J Urol2007; 177: 1390–1394.
15.
RothrockNELutgendorfSKKrederKJ, et al.Stress and symptoms in patients with interstitial cystitis: a life stress model. Urology2001; 57: 422–427.
16.
CoxAGoldaNNadeauG, et al.CUA Guideline: diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Can Urol Assoc J2016; 10: E136–E135.
17.
SuskindAMBerrySHEwingBA, et al.The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND interstitial cystitis epidemiology male study. J Urol2013; 189: 141–145.
18.
BerrySHElliottMNSuttorpM, et al.Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol2011; 186: 540–544.
19.
LoweHToyangNSteeleB, et al.The endocannabinoid system: a potential target for the treatment of Various diseases. Int J Mol Sci2021; 22: 9472.
20.
KilaruAChapmaKD. The endocannabinoid system. Essays Biochem2020; 64: 485–499.
21.
MunroSThomasKLAbu-ShaarM. Molecular characterization of a peripheral receptor for cannabinoids. Nature1993; 365: 61–65.
HowlettAC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat2002; 68–69: 619–631.
24.
GratzkeCStrengTParkA, et al.Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder. J Urol2009; 181: 1939–1948.
25.
GaliègueSMarySMarchandJ, et al.Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem1995; 232: 54–61.
26.
ChiouL-CHuSS-JHoY-C. Targeting the cannabinoid system for pain relief?Acta Anaesthesiol Taiwan2013; 51: 161–170.
27.
MakriyannisAMechoulamRPiomelliD. Therapeutic opportunities through modulation of the endocannabinoid system. Neuropharmacology2005; 48: 1068–1071.
28.
PacherPBátkaiSKunosG. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev2006; 58: 389–462.
29.
TambaroSCasuMAMastinuA, et al.Evaluation of selective cannabinoid CB1 and CB2 receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis. Eur J Pharmacol2014; 729: 67–74.
30.
BergerGAroraNBurkovskiyI, et al.Experimental cannabinoid 2 receptor activation by phyto-derived and synthetic cannabinoid ligands in LPS-induced interstitial cystitis in mice. Molecules2019; 24: 4239.
31.
KuwahataHKatsuyamaSKomatsuT, et al.Local peripheral effects of β-caryophyllene through CB2 receptors in neuropathic pain in mice. Pharmacol Pharm2012; 3: 397–403.
32.
KlaukeA-LRaczIPradierB, et al.The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol2014; 24: 608–620.
33.
GertschJLeontiMRadunerS, et al.Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A2008; 105: 9099–9104.
34.
VenkatakrishnaKSundeepKSudeepHV, et al.ViphyllinTM, a standardized black pepper seed extract exerts antinociceptive effects in murine pain models via activation of cannabinoid receptor CB2, peroxisome proliferator-activated receptor-alpha and TRPV1 Ion channels. J Pain Res2022; Volume 15: 355–366.
35.
YoussefDAEl-FayoumiHMMahmoudMF. Beta-caryophyllene protects against diet-induced dyslipidemia and vascular inflammation in rats: involvement of CB2 and PPAR-γ receptors. Chem Biol Interact2019; 297: 16–24.
36.
HashieshHMSharmaCGoyalSN, et al.A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of β-caryophyllene, a dietary cannabinoid. Biomed Pharmacother2021; 140: 111639.
37.
GhelardiniCGaleottiNDiL, et al.Local anaesthetic activity of b-caryophyllene. Il Farmaco2001; 56: 387–389.
38.
SantosPSOliveiraTCR. JúniorLM, et al.β-caryophyllene delivery systems: enhancing the oral pharmacokinetic and stability. Curr Pharm Des2018; 24: 3440–3453.
39.
RivaAMorazzoniPArtariaC, et al.A single-dose, randomized, cross-over, two-way, open-label study for comparing the absorption of boswellic acids and its lecithin formulation. Phytomedicine2016; 23: 1375–1382.
40.
RivaARonchiMPetrangoliniG, et al.Improved oral absorption of quercetin from quercetin phytosome®, a new delivery system based on food grade lecithin. Eur J Drug Metab Pharmacokinet2019; 44: 169–177.
41.
SemaltyASemaltyMRawatMSM, et al.Supramolecular phospholipids–polyphenolics interactions: the PHYTOSOME® strategy to improve the bioavailability of phytochemicals. Fitoterapia2010; 81: 306–314.
HüschJBohnetJFrickerG, et al.Enhanced absorption of boswellic acids by a lecithin delivery form (phytosome®) of Boswellia extract. Fitoterapia2013; 84: 89–98.
44.
HopkinsWJGendron-FitzpatrickABalishE, et al.Time course and host responses to Escherichia coli urinary tract infection in genetically distinct mouse strains. Infect Immun1998; 66: 2798–2802.
45.
DicksonKScottCWhiteH, et al.Antibacterial and analgesic properties of Beta-caryophyllene in a murine urinary tract infection model. Molecules2023; 28: 4144.
46.
RomSZuluaga-RamirezVDykstraH, et al.Selective activation of cannabinoid receptor 2 in leukocytes suppresses their engagement of the brain endothelium and protects the blood-brain barrier. Am J Pathol2013; 183: 1548–1558.
47.
Varga ZVMatyasCErdelyiK, et al.Β-Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and metabolic dysregulation in mice. Br J Pharmacol2018; 175: 320–334.
48.
KimSDChoKJKimJC. Expression of cannabinoid 1 and, 2 receptors and the effects of cannabinoid 1 and, 2 receptor agonists on detrusor overactivity associated with bladder outlet obstruction in rats. BMC Urol2017; 17: 21.
49.
YoussefDAEl-FayoumiHMMahmoudMF. Beta-caryophyllene alleviates diet-induced neurobehavioral changes in rats: the role of CB2 and PPAR-γ receptors. Biomed Pharmacother2019; 110: 145–154.
50.
HartmannPSzabóAErősG, et al.Anti-inflammatory effects of phosphatidylcholine in neutrophil leukocyte-dependent acute arthritis in rats. Eur J Pharmacol2009; 622: 58–64.
51.
ChenMHuangHZhouP, et al.Oral phosphatidylcholine improves intestinal barrier function in drug-induced liver injury in rats. Gastroenterol Res Pract2019; 2019: 1–6.
52.
HagnGHolbeinBZhouJ, et al.Anti-inflammatory iron chelator, DIBI, reduces leukocyte-endothelial adhesion and clinical symptoms of LPS-induced interstitial cystitis in mice. Clin Hemorheol Microcirc2021; 79: 395–406.
53.
KowalewskaPMBurrowsLLFox-RobichaudAE. Intravital microscopy of the murine urinary bladder microcirculation. Microcirculation2011; 18: 613–622.
54.
ChuRUmukoroNGreerT, et al.Intravenous lidocaine infusion for the management of early postoperative pain: a comprehensive review of controlled trials intravenous lidocaine infusion for the management of early postoperative pain. Psychopharmacol Bull2020; 50: 216–259.
55.
de AraujoDRCeredaCMSBrunettoGB, et al.Pharmacological and local toxicity studies of a liposomal formulation for the novel local anaesthetic ropivacaine. J Pharm Pharmacol2008; 60: 1449–1457.
